

Ministry of Health  
Drugs and Devices Division

## **Notice from the Executive Officer: Funding of Truxima (rituximab) under the Ontario Drug Benefit Program**

March 30, 2020

Effective **March 31, 2020**, Truxima (rituximab) will be listed on the ODB Formulary/Comparative Drug Index (Formulary) as a Limited Use (LU) benefit for eligible ODB recipients for the treatment of Rheumatoid Arthritis (RA).

Details of the LU criteria for RA will also be posted in the March 2020 Formulary update which can be found on the ministry's website at:

[http://www.health.gov.on.ca/en/pro/programs/drugs/edition\\_43.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx)

Effective **March 16, 2020**, Truxima became funded for specific oncology indications through the Ministry's New Drug Funding Program (NDFP) overseen by Ontario Health (Cancer Care Ontario). The funding criteria for Truxima for oncology indications can be found on Cancer Care Ontario's website at

<https://www.cancercareontario.ca/en>

To further inform healthcare providers and patients, we have also included a Frequently Asked Questions (FAQs) document for reference purposes.

### **Additional Information:**

#### **For pharmacies:**

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

#### **For all other Health Care Providers and the Public:**

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.

---